Extract
Mepolizumab and benralizumab are monoclonal antibodies (mAbs) approved for the treatment of severe eosinophilic asthma (SEA), targeting IL-5 and IL-5R respectively [1]. In appropriately selected patients, their use leads to significant reductions in asthma exacerbations and maintenance oral corticosteroid (mOCS) dose [2, 3].
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Hearn has nothing to disclose.
Conflict of interest: Mr. Hug has nothing to disclose.
Conflict of interest: Ms. Somani has nothing to disclose.
Conflict of interest: Dr. Kavanagh reports other from Teva, outside the submitted work.
Conflict of interest: Dr. d'Ancona reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from Napp, outside the submitted work.
Conflict of interest: Ms. Roxas has nothing to disclose.
Conflict of interest: Ms. Green has nothing to disclose.
Conflict of interest: Ms. Thomson has nothing to disclose.
Conflict of interest: Ms. Fernandes has nothing to disclose.
Conflict of interest: Dr. Kent reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, from Napp, outside the submitted work.
Conflict of interest: Dr. Dhariwal reports other from Sanofi, outside the submitted work.
Conflict of interest: Dr. Nanzer reports other from Napp, personal fees from Astrazeneca, outside the submitted work.
Conflict of interest: Dr. Jackson reports personal fees and other from Teva, personal fees from GSK, personal fees from Astra Zeneca, personal fees from Chiesi, personal fees from Napp, outside the submitted work.
- Received December 16, 2020.
- Accepted February 4, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
